



THIRD-PARTY TESTING SUMMARY

Quality Results Summary • Target Specification: 10 mg per vial

PRODUCT FOXO4-DRI	LOT / BATCH 202610FOXO4	TEST DATE October 2, 2026	TESTING SOURCE Third-Party University Tested	OVERALL STATUS PASS
----------------------	----------------------------	------------------------------	---	-------------------------------

Analytical Results

Test	Method	Specification	Reported Result	Status
Identity	LC-MS	Consistent with declared peptide	Consistent with FOXO4-DRI	PASS
Purity	RP-HPLC	≥ 98.00%	99.62%	PASS
Peptide Content	Quantitative assay	Target: 10 mg/vial	10.18 mg/vial	PASS
Endotoxin	Endotoxin assay	Reported as EU/mg	<0.25 EU/mg	PASS
Sterility	Sterility test	Meets test requirements	No growth detected	PASS

PURITY & IDENTITY GUARANTEE

Base Peptides stands behind the reported purity and identity results for the specific lot identified above. Products covered by this summary are supported by our money-back guarantee, subject to the terms of our refund policy.

Document purpose and limitations. This Base Peptides document is a customer-facing summary of results supplied to Base Peptides from third-party university testing. It is not a laboratory-issued certificate of analysis, original laboratory report, endorsement, certification, or approval by the testing institution. Results apply only to the product and lot identified on this page. This summary is not intended to diagnose, treat, cure, or prevent any disease and does not replace the product label, instructions, or applicable terms and policies.